Edison Issues Report on MindMaze Therapeutics (MMTX)
London, United Kingdom–(Newsfile Corp. – April 7, 2026) – Edison issues report on MindMaze Therapeutics (SIX: MMTX).
MindMaze Therapeutics is a commercial-stage health technology company pioneering AI-driven digital neurotherapeutic solutions for treatment and recovery after neurological events such as stroke and traumatic brain injury (TBI). Its unique, integrated and coordinated platform spans the full continuum of care from acute treatment to at-home recovery, providing differentiation and helping to avert treatment gaps. With US FDA and CE/MDR registrations and a unique US CPT Category III (CAT III) reimbursement for home-based therapy, MindMaze is primed for commercial roll-out across the US and Europe.
Click here to read the full report.
All reports published by Edison are available to download free of charge from its website:
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.
For more information, please contact Edison:
enquiries@edisongroup.com
+44 (0)20 3077 5700
Connect with Edison on:
LinkedIn www.linkedin.com/company/edison-group-/
X www.x.com/edison_inv_res
YouTube www.youtube.com/edisonitv
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/291443
View more news from Edison Group
You are receiving this email because you have previously indicated your interest in receiving news for Edison Group
If you no longer want to receive messages from us, you can click here to unsubscribe.
Anti-Spam Policy | Privacy Policy
The post Edison Issues Report on MindMaze Therapeutics (MMTX) first appeared on PressReleaseCC.
Pingback: Edison Issues Report On MindMaze Therapeutics (MMTX) - AWNews